So, let’s not denigrate new drugs that are not first-in-class upon FDA approval. These can be valuable new medicines whose true value will be determined only after significant use in patients.
from Forbes Real Time https://www.forbes.com/sites/johnlamattina/2017/12/11/biopharma-schizophrenia-high-demand-for-innovation-vs-pleas-for-me-too-drugs/
via IFTTT
No comments:
Post a Comment